Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CBFB
REST API REST API
Homo sapiens
CBFB is differentially expressed in 342 experiments: 139 organism parts: liver, heart, ... (137 more);, 238 disease states: normal, glioblastoma, ... (236 more);, 107 cell types 435 cell lines 51 compound treatments and 85 other conditions.
Synonyms PEBP2B
Orthologs Cbfb (Mus musculus)   Q4H3S2_CIOIN (Ciona intestinalis)   Cbfb (Rattus norvegicus)   Q8QGE8_CHICK (Gallus gallus)   cbfb (Danio rerio)   CBFB (Bos taurus)   Bgb (Drosophila melanogaster)   Bro (Drosophila melanogaster)   cbfb (Xenopus laevis)   CBFB (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, protein binding, regulation of transcription, DNA-dependent, transcription from RNA polymerase II promoter, positive regulation of transcription from RNA polymerase II promoter, transcription coactivator activity, nucleus, cellular_component, definitive hemopoiesis, osteoblast differentiation, ossification, lymphocyte differentiation, cell maturation, myeloid cell differentiation, sequence-specific DNA binding transcription factor activity
InterPro Term CBF_beta
UniProt Accession Q13951
Gene-Disease Assocation LEUKEMIA, ACUTE MYELOID; AML
Search EB-eye ENSG00000067955
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, E-GEOD-8167, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (40 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529
SW480
3
E-MEXP-1014, E-GEOD-2509, E-GEOD-18005
BT-474
2
E-GEOD-3529, E-GEOD-5823
AGS
2
E-MTAB-37, E-GEOD-15460
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
429 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, ... (49 experiments)

Factor Value U/D Experiments
neutrophil
3
E-GEOD-12662, E-GEOD-3982, E-GEOD-995
hematopoietic stem cell
2
E-MEXP-872, E-MEXP-1403
human foreskin fibroblast
2
E-GEOD-18147, E-GEOD-18265
induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
101 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-MTAB-62, ... (66 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-37, E-MTAB-62, E-MEXP-231, E-GEOD-2514
dermatomyositis
3
E-GEOD-5370, E-GEOD-1551, E-MTAB-62
colorectal adenocarcinoma
3
E-MTAB-62, E-AFMX-5, E-MTAB-37
control
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-20295
prostate carcinoma
1
3
E-MTAB-62, E-GEOD-96, E-MTAB-37, E-MEXP-1327
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
232 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-7400, E-GEOD-1417, E-TABM-782, E-GEOD-697, ... (31 experiments)

Factor Value U/D Experiments
R547
1
E-GEOD-15389
TTA
1
E-MEXP-2590
granulocyte-colony stimulating factor
1
E-GEOD-7400
glutamine
1
E-MEXP-1335
5-fluorouridine
1
E-GEOD-995
cadmium chloride 2.5-hydrate
1
E-GEOD-6907
45 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
32
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-1140, E-GEOD-860, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1614, E-GEOD-1638, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-2509, E-TABM-147, ... (8 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-2466, E-GEOD-22593, E-GEOD-18005, ... (14 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, E-GEOD-10315, ... (15 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-2466, E-MEXP-2069, ... (36 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-MEXP-561, E-GEOD-980, E-GEOD-17400, ... (7 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-MEXP-2177

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phenotype
studied in E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (8 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, ... (8 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.416 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM